{"url_path":"/sec/tpst/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-224156-index.html","accession_number":"0001193125-26-224156","cik":"0001544227","ticker":"TPST","issuer_name":"Tempest Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-224156-index.html","primary_entity_key":"0001544227","primary_entity_name":"Tempest Therapeutics, Inc."},"word_count":140,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn May 14, 2026, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and other business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\n \n\nThe foregoing information (including Exhibit 99.1 hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing."}